About: Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19
Creator	Esposito, Giovanni Marfella, Raffaele Paolisso, Giuseppe Sardu, Celestino Gargiulo, Giuseppe
Source	Medline; PMC
abstract	A possible association could exist between type 2 diabetes mellitus (T2DM) and Coronavirus-19 (Covid-19) infection. Indeed, patients with T2DM show high prevalence, severity of disease and mortality during Covid-19 infection. However, the rates of severe disease are significantly higher in patients with diabetes compared with non-diabetes (34.6% vs. 14.2%; p < 0.001). Similarly, T2DM patients have higher rates of need for Intensive Care Unit (ICU, 37.0% vs. 26.7%; p = 0.028). Thus, about the pneumonia of Covid-19, we might speculate that the complicated alveolar-capillary network of lungs could be targeted by T2DM micro-vascular damage. Therefore, T2DM patients frequently report respiratory symptoms and are at increased risk of several pulmonary diseases. In addition, pro-inflammatory pathways as that involving interleukin 6 (IL-6), could be a severity predictor of lung diseases. Therefore, it looks intuitive to speculate that this condition could explain the growing trend of cases, hospitalization and mortality for patients with T2DM during Covid-19 infection. To date, an ongoing experimental therapy with monoclonal antibody against the IL-6 receptor in Italy seems to have beneficial effects on severe lung disease and prognosis in patients with Covid-19 infection. Therefore, should patients with T2DM be treated with more attention to glycemic control and monoclonal antibody against the IL-6 receptor during the Covid-19 infection?
has issue date	2020-06-11(xsd:dateTime)
bibo:doi	10.1186/s12933-020-01047-y
bibo:pmid	32527257
has license	cc-by
sha1sum (hex)	2816662a2375878b62c01fd23183a243cd929bf1
schema:url	https://doi.org/10.1186/s12933-020-01047-y
resource representing a document's title	Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19
has PubMed Central identifier	PMC7289072
has PubMed identifier	32527257
schema:publication	Cardiovasc Diabetol
resource representing a document's body	covid:2816662a2375878b62c01fd23183a243cd929bf1#body_text
is schema:about of	named entity 'patients' named entity 'COVID-19 INFECTION' named entity 'prevalence' named entity 'Impact' named entity 'diabetes mellitus' named entity 'infection' named entity 'co-morbidity' named entity 'T2DM' named entity 'T2DM' named entity 'insulin' named entity 'IL-18' named entity 'monoclonal antibody' named entity 'IL-6 receptor' named entity 'infection' named entity 'IL-6' named entity 'alveolar' named entity 'cardiovascular' named entity 'lung' named entity 'metalloproteinase' named entity 'T2DM' named entity 'COVID' named entity 'critically ill patients' named entity 'infectious disease' named entity 'capillary network' named entity 'interstitial fibrosis' named entity 'diabetes' named entity 'pneumonia' named entity 'T2DM' named entity 'systemic inflammation' named entity 'meta-analysis' named entity 'ICU' named entity 'IL-6' named entity 'Italy' named entity 'T2DM' named entity 'infection' named entity 'infection' named entity 'critically ill patients' named entity 'Intensive Care Unit' named entity 'T2DM' named entity 'coronavirus disease 2019' named entity 'diabetes' named entity 'pathogenesis' named entity 'inflammatory cytokine' named entity 'composite endpoint' named entity 'inflammation' named entity 'plasma levels' named entity 'T2DM' named entity 'IL-6 receptor' named entity 'T2DM' named entity 'intensive therapy' named entity 'molecular mechanisms' named entity 'variance' named entity 'biological agents' named entity 'monoclonal antibody' named entity 'cytokine release syndrome' named entity 'IL-6' named entity 'MMP-12' named entity 'lung disease' named entity 'Covid' named entity 'reduces inflammation' named entity 'diabetes' named entity 'glucose homeostasis' named entity 'pro-inflammatory cytokines' named entity 'risk stratification' named entity 'ICU' named entity 'T2DM' named entity 'Covid' named entity 'ICU' named entity 'risk stratification' named entity 'prognosis' named entity 'T2DM' named entity 'diabetes' named entity 'Covid' named entity 'T2DM' named entity 'T2DM' named entity 'interleukin 6' named entity 'T2DM'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software